

## INDEX

Note: Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.

- AAP. See *American Academy of Pediatrics*.
- Abbreviations, x, 465-469
- ACAM2000 (smallpox vaccine), 436t-437t  
CPT and ICD-9-CM codes, 139t  
efficacy/immunogenicity, 437  
safety, 437-440
- Acetaminophen, 127
- ACIP. See *Advisory Committee on Immunization Practices*.
- Acquired immunodeficiency syndrome (AIDS), polio vaccine and, 257. See also *Human immunodeficiency virus (HIV)*.
- ActHIB (Hib, PRP-T conjugate), 284, 286t-287t  
cost of (purchase price), 150t  
CPT and ICD-9-CM codes, 137t  
efficacy/immunogenicity, 284
- Active Bacterial Core, 62
- Active immunization, 13-18
- Acute otitis media (AOM), 355, 356, 357
- Acyclovir, 196
- Ad-hoc committees and task forces, 65-66
- Adacel (Tdap), 272t-274t. See also *Tdap vaccine*.  
cost of (purchase price), 151t  
CPT and ICD-9-CM codes, 139t  
immunogenicity of, 275  
schedule for, 189t-190t, 273t
- Adaptive immune system, 19, 25-28
- Adenocarcinomas, HPV and, 307
- Adenovirus types 4 and 7, 454t
- Adenylate cyclase toxin, 268
- Adjuvants, 28, 379. See also *specific vaccines*.
- Administration of intravenous immune globulin, 127, 164t-166t
- Administration of vaccines, 122-129, 155-166. See also *Delivery of vaccines; Doses of vaccine*.  
anxiety, pain, and fever, dealing with, 127  
CPT codes for, 144t-146t  
emergencies following. See *Emergencies, dealing with*.  
general issues, 122-123  
general rules for, 155-166  
intervals between vaccines, 156, 158t-161t  
intervals for live vaccines and antibody-containing products, 164t-166t  
intramuscular, 123, 126  
intranasal, 126-127  
multiple vaccines, simultaneous administration of, 68t, 94, 238-240  
oral administration, 123-126  
preferred sites and needle length, 128t-129t  
route and site of, 23, 163  
schedules for, 179, 180t-192t  
subcutaneous, 123, 126  
techniques in, 166  
vaccine mix-ups, 163-166
- Adolescent immunization  
coverage, 60, 90t  
new recommendations, 95, 271  
schedules  
catch-up, 187t-188t  
hepatitis B, 297-301  
HPV vaccine, 308-309, 312  
routine, 183t-184t  
syncope and, 130
- Adoptees, international, 210-211
- Adult immunization  
coverage goals, 90t  
schedules  
by age group, 189t-190t  
hepatitis B, 301-302  
by medical condition, 191t-192t  
standards for, 95-96, 96t
- Adverse events, 63-64. See also *Vaccine safety net*.  
association vs causation, 241  
most common, 63-64  
package insert, inclusion in, 54  
Reportable Events Table, 100t-101t  
Vaccine Adverse Event Reporting System, 63-64, 98-99
- Advertising claims, package insert and, 54
- Advisory Committee on Immunization Practices (ACIP), 55-58, 56, 459  
composition of, 55-56  
recommendations (“Pink Book”), viii-ix, 57  
vaccination schedules, 179, 180t-192t
- Advocacy organizations, 460-461
- AFIX (Assessment, Feedback, Incentives, eXchange of information), 122
- Afluria (TIV, influenza, split virus), 316t-320t  
CPT and ICD-9-CM codes, 137t
- Agammaglobulinemia, 18
- Age. See also *Schedules for routine immunizations*.  
definition of, x  
grace period for immunizations, 108  
minimum ages for routine vaccines, 156, 158t-161t  
needle type and injection site and, 128t-129t
- AIDS, polio vaccine and, concerns about, 257. See also *Human immunodeficiency virus (HIV)*.
- All Kids Count, 460
- Allergies, vaccines and, 167, 169t-171t, 173t-174t, 253-254
- Allied Vaccine Group, 460
- Alphaviruses, bioterrorism potential, 83t
- American Academy of Family Physicians (AAFP), 460  
recommendations, 57, 179
- American Academy of Pediatrics (AAP), 460  
recommendations, 57, 179  
Red Book, viii-ix, 57, 462
- American College Health Association (ACHA), 460
- American Nurses Association (ANA), 460
- American Pharmacists Association (APA), 460
- American Public Health Association (APHA), 460
- Anamnestic response, 28, 29, 30-31

Anaphylaxis/anaphylactic shock, 100t, 130-131, 169t, 171t  
  symptoms, 130  
  treatment, 131  
Anesthetics, topical, 127  
Animal products, in vaccine manufacturing, 254-256  
Animal viruses, natural attenuation for humans, 16  
Animal workers, vaccination of, 221t, 292, 409, 424t  
Anogenital warts, HPV and, 307  
Anthrax, 405-410  
  antibiotic therapy for, 405  
  as bioterrorism agent, 77, 82t, 405-406  
  clinical features, 405  
  epidemiology and transmission, 405-406  
  nomenclature, 470t  
  pathogen, 405  
  vaccines for, 82t, 408t  
    background on immunization program, 406-407  
    contraindications/precautions, 408-409  
    CPT and ICD-9-CM codes, 136t  
    efficacy/immunogenicity, 407  
    postexposure vaccination, 409  
    pre-exposure vaccination, 407, 409  
    recommendations, 409-410  
    safety, 407-409  
Anthrax Vaccine Immunization Program, 407  
Antibodies, 19-25. See also *Immune globulin*; *Immunity, testing for*.  
  action mechanisms and sites, 23  
  engineered, 19  
  extrafollicular reaction and, 24-25, 24  
  genetic determinants of antibody responses, 31  
  germline, 24, 24  
  measurement of, 38-39  
  passive immunization with, 13, 18-19  
  pathways of production, 24-31, 24  
  persistence of, 30-31  
  specificity of, 23, 29-30  
  as surrogates of protection, 38-39  
  time course of responses, 29  
Antigen-presenting cells (APCs), 25-26, 27  
Antigens, 19-23  
  antigenic competition, 379  
  antigenic drift/antigenic shift, 313  
  number of, in routine vaccines, 239t  
Antitoxins, in passive immunization, 19  
Anxiety, dealing with, 127  
AOM. See *Acute otitis media*.  
APCs. See *Antigen-presenting cells*.  
Apoptosis, 35  
Arthritis, impaired immunity and, 198  
Arthus-type reaction, 169t, 173t, 278  
Aspirin use, as contraindication/precaution, 171t, 174t, 221t, 324, 370  
Asplenia, impaired immunity and, 199-200, 342  
Assessment, resources on, 461  
Association for Prevention Teaching and Research (APTR), 460

Asthma  
  as contraindication, 171t, 325  
  impaired immunity and, 198  
Atopic dermatitis, as contraindication, 172t, 438  
Attenuation of vaccines, 13-17, 14t-15t  
  engineered, 16-17  
  heterologous host, 16  
  serial passage, 13-16  
Attenuvax (measles, live, SC), 138t  
Autism  
  MMR vaccine and, 68t, 69t, 240-243, 242, 244  
  thimerosal and, 245-249, 247, 248, 250t  
Autoimmune disease, vaccines and, 253-254  
Avian flu (influenza A; H5N1), 410-412  
  
B cells  
  antibody production by, 23, 24-25, 24  
  clonal expansion of, 23, 28  
  interaction with Th cells, 26-28, 27  
  memory, 28, 30  
BabyBIG (botulism immune globulin, human), 141t  
Bacille Calmette-Guérin (BCG), 16, 156, 454t  
*Bacillus anthracis*, 82t, 470t. See also *Anthrax*.  
Bacteremia, 355, 356  
Bacteria. See also *specific bacteria*.  
  attenuation of, 13-16  
  complement-mediated lysis of, 23  
  opsonization of, 23  
Bacterial vaccines, 17  
Baker's yeast, allergy to, 170t, 312  
BayTet (TIG), 268  
BCG. See *Bacille Calmette-Guérin*.  
Behavioral Risk Factor Surveillance System (BRFSS), 60, 61, 461  
Billing. See *Coding and billing*.  
Biologics License Application (BLA), 53  
Bioterrorism, 76-77, 82t-83t  
BioThrax, 136t, 407-410, 408t  
Bird flu (influenza A; H5N1), 410-412  
Birth Cohort Study (Montréal)  
  MMR and autism, 241, 242  
  thimerosal and autism, 246, 247  
BLA (Biologics License Application), 53  
Blood transfusion (IV), interval for receipt of live vaccines after, 164t-165t  
Bloodborne Pathogens Standard, 102-107  
Bone marrow transplantation. See *Hematopoietic stem cell transplantation*.  
Booster vaccination, 29, 29  
Boostrix (Tdap), 272t-274t. See also *Tdap vaccine*.  
  cost of (purchase price), 151t  
  CPT and ICD-9-CM codes, 139t  
  immunogenicity, 275  
  schedule for, 183t, 273t  
*Bordetella pertussis*, 17, 267-268, 269, 470t. See also *Pertussis*.  
*Borrelia burgdorferi*, 454t  
Botulinum antitoxin, 141t

Botulinum toxin, 82t  
 Botulism  
   bioterrorism potential and US vaccine status, 82t  
   immune globulin, CPT and ICD-9-CM codes, 141t  
 Bovine materials, vaccine production and, 254-256  
 Breast-feeding  
   as contraindication for vaccination, 173t, 207  
   rotavirus vaccination and, 354  
   vaccine use during, 207  
 BRFSS. See *Behavioral Risk Factor Surveillance System*.  
 The Brighton Collaboration, 65, 460  
 Brucellosis, bioterrorism potential and US vaccine status, 82t  
 Buffers, 167, 379  
*Burkholderia mallei*, bioterrorism potential, 83t  
*Burkholderia pseudomallei*, bioterrorism potential, 83t  
 Butte County, California, 40, 41, 289  
  
*Campylobacter jejuni* enteritis, 251  
 Cancer, vaccines and, 256-257, 303-307  
 Carimune NF (immune globulin, human), 140t  
 Catch-up immunization schedules  
   children, age 4 months-6 years, 185t-186t  
   children, age 7-18 years, 183t, 187t-188t  
 CD4 counts, 194, 201-203, 202t  
 CDC. See *Centers for Disease Control and Prevention*.  
 CEBR. See *Centers for Biologics Evaluation and Research*.  
 Cell-mediated immunity defects, 197  
 Centers for Biologics Evaluation and Research (CEBR), 56, 459  
 Centers for Disease Control and Prevention (CDC), 459  
   monitoring and surveillance, 62  
   quality improvement methodology (AFIX and CoCASA), 122  
   vaccine policy and, 55, 56  
   vaccine stockpiles, 76, 411, 431, 434  
 Cervarix (HPV2), 137t, 312  
 Cervical cancer, HPV and, 303-307, 308, 309  
 Cervical cancer screening, 312  
 Cervical intraepithelial neoplasia (CIN) grades, 307, 309  
 Chemotherapy  
   impaired immunity and, 198-199  
   initiation of, *S pneumoniae* vaccination and, 361  
 Chickenpox. See *Varicella*.  
 Childhood Immunization Support Program, 58  
 Children. See also *Infants*.  
   consent for immunization, 102  
   coverage, *Healthy People 2010* goals, 90t-91t  
   HIV-exposed or infected, vaccination issues, 196, 200-203  
   immunization practice standards, 88-95  
   immunization schedules  
     catch-up, age 4 months-6 years, 185t-186t  
     catch-up, age 7-18 years, 183t, 187t-188t  
     hepatitis B, 297-301  
     influenza, 315  
     routine, age 0-6 years, 180t-182t, 362t-363t  
     routine, age 7-18 years, 183t-184t  
   polysaccharide vaccines and, 25  
   Children's Hospital of Philadelphia Vaccine Education Center, 460  
   Children's Vaccine Program at PATH, 460  
   *Chlamydophila psittaci*, bioterrorism potential, 83t  
   Cholera, 454t  
   Chronic disease, impaired immunity and, 200  
   Chronic granulomatous disease, influenza vaccine and, 193  
   Cidofovir, 439  
   CISA. See *Clinical Immunization Safety Assessment (CISA) Network*.  
   Classification of vaccines, 13, 14t-15t  
   Clinical Immunization Safety Assessment (CISA) Network, 65, 461  
   Clinical trials, 51-53, 52  
   Clonal expansion, 23  
   *Clostridium botulinum*, 82t. See also *Botulism*.  
   *Clostridium tetani*, 267, 269, 470t. See also *Tetanus*.  
   CoCASA (Comprehensive Clinic Assessment Software Application), 122  
   Cochlear implants, vaccination and, 222t, 361  
   Coding and billing, 131-135, 134t, 136t-142t, 144t-148t  
   CPT (Current Procedural Terminology) codes, 131-133, 144t-147t  
     for immune globulin administration, 147t  
     for preventive medicine services, 134t  
     for routine office visit at 6 months, 148t  
     for vaccine administration, 144t-146t  
     for vaccines and immune globulins, 136t-142t  
   ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes, 133, 148t  
     for preventive medicine services, 134t  
     for routine office visit, 148t  
     for vaccines and immune globulins, 136t-142t  
   National Drug Codes (NDCs), 133-134  
   College students, vaccination of, 221t, 325, 333  
   Combination vaccines, 378-387, 382t-386t, 388t-389t  
     advantages and disadvantages of, 381t  
     background, 378-379  
     development, evaluation, and licensure of, 379-380  
     nomenclature, 471t  
     noninferiority standard, 380  
     notation conventions, x  
     overimmunization and, 380  
     preference for, 380  
     quality, effect on, 381-387  
     recommendations on, 380  
   Communicating about vaccines, viii, 223-266. See also *Concerns about vaccines, addressing*.  
     communicating risks and benefits, 223-228  
     parent phenotypes regarding vaccination, 229t  
     physician option of withdrawing from case, 232  
     specific concerns of parents and patients, 235-258  
     tips for communicating, 227-228  
     trust in, 227, 232  
     vaccine refusal, 228-232  
   Complement deficiencies, 193-194, 197-198, 342  
   Complement-mediated lysis, 23  
   Component vaccines, 14t-15t, 17-18  
   Comprehensive Clinic Assessment Software Application (CoCASA), 122, 461

- Comvax (HepB-Hib), 382t-386t  
 cost of (purchase price), 150t  
 CPT and ICD-9-CM codes, 137t  
 schedule for, 297
- Concerns about vaccines, addressing, 223-266  
 communicating risks and benefits, 223-228, 224, 229t  
 costs of public concern, 232-233  
 specific concerns, 235-258  
   AIDS, polio vaccine and, 257  
   allergies and autoimmune disease, vaccines and, 253-254  
   autism, MMR vaccine and, 240-243, 242  
   autism, thimerosol and, 245-249  
   brain damage, pertussis vaccine and, 249-251  
   cancer, vaccines and, 256-257  
   fetal tissue and vaccines, 252-253  
   Guillain-Barré syndrome, vaccines and, 251-252  
   mad cow disease, vaccines and, 254-256  
   multiple sclerosis (MS), vaccines and, 252  
   multiple vaccines, immune overload and, 238-240  
   natural infection vs immunization, 237-238  
   necessity for vaccines, 235-237  
   SIDS, vaccines and, 258  
   vaccine protest organizations, 233-235, 234, 235t, 236t  
   vaccine refusal, 228-232
- Condyloma acuminata, HPV and, 307
- Confidentiality, protecting, 119-120
- Contaminants, 167. See also *specific vaccines*.
- Contraindications and precautions, 167-168, 169t-175t. See also *specific vaccines*.  
 contraindication, defined, 167  
 erroneous contraindication, 176t-177t  
 impaired immunity and, 193  
 precaution, defined, 167-168  
 screening for, 122, 124t-125t
- Correctional facility staff, vaccination of, 222t
- Correlates of protection, 37-39
- Corynebacterium diphtheriae*, 267, 269, 470t. See also *Diphtheria*.
- Costs  
 cost-benefit analysis, 47, 48t  
 of influenza vaccination, 315  
 of *N meningitidis* vaccination, 337  
 of rotavirus vaccination, 350  
 of varicella vaccination, 367  
 of zoster (shingles) vaccination, 375  
 provider costs for vaccination services, 135, 153t  
 public/private sector participation in, 67-73, 71  
 of routine childhood vaccinations, 70t  
 state financing models, 73-74, 73  
 of vaccine development, 67-74  
 of vaccine-preventable diseases, 95-96  
 of vaccines (purchase price), 134-135, 149t-152t
- Coverage, 58-62, 59, 61  
 combination vaccines and, 387  
*Healthy People 2010* goals, 88, 90t-93t  
 resources on, 461
- Cowpox, 16
- Coxiella burnetii*, bioterrorism potential, 83t
- CPT (Current Procedural Terminology) codes, 131-133, 144t-147t  
 for immune globulin administration, 147t  
 for preventive medicine services (new vs established patient), 134t  
 for routine office visit at 6 months, 148t  
 for vaccine administration, 144t-146t  
 for vaccines and immune globulins, 136t-142t  
 Creutzfeldt-Jakob disease, variant (vCJD), 254-256
- Criteria for immunity  
 measles, mumps, and rubella, 334t  
 varicella, 371t
- Cross-protection, 30
- Current Procedural Terminology codes. See *CPT (Current Procedural Terminology) codes*.
- CytoGam (CMV immune globulin, human, IV), 141t
- Cytokines, 25, 26, 405
- Cytomegalovirus immune globulin intravenous (CMV-IGIV), 141t, 165t
- Cytotoxic T cells (Tc cells), 26, 31-37, 34  
 action mechanisms, 34, 35, 36  
 implications for vaccination, 35-37
- Cytotoxins, 35
- Danish Cohort Study  
 Hib vaccine and diabetes, 254, 255  
 MMR and autism, 243, 244  
 thimerosol and autism, 246-249, 248
- Daptacel (DTaP), 272t-274t  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t  
 efficacy, 272
- Day care center staff, vaccination of, 222t, 293, 325
- Decavac (Td, preservative-free), 276t-277t  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 139t
- Delivery of vaccines  
 improving, 116-118  
   expanding access, 118  
   Immunization Information Systems (IISs), 119-121, 120t  
   missed opportunities, 118  
   other strategies, 121-122  
   reminder, recall, and tracking systems, 116-118  
   standing orders, 118-119  
   monitoring, 58-62
- Dendritic cells, 25-26, 27
- Department of Defense (DOD), 459
- Department of Health and Human Services, 459
- Dermatitis, as contraindication for vaccination, 172t
- Development. See *Vaccine development and licensure*.
- Diabetes  
*S pneumoniae* vaccination and, 361  
 vaccines and, 254, 255
- DiGeorge syndrome, 65, 167  
 impaired immunity and vaccination, 194, 197

- Diphtheria, 267-280  
 antitoxin, CPT and ICD-9-CM codes, 141t  
 clinical features, 268  
 epidemiology and transmission, 269  
*Healthy People 2010* objectives for, 92t  
 morbidity and mortality from, 46t  
 pathogen, 267  
 toxoid, 151t, 276t-277t  
 vaccines for, 272t-274t, 276t-277t. See also *DT*; *DTaP vaccine*; *Tdap vaccine*.  
 adult. See *Tdap vaccine*.  
 background on immunization program, 270  
 children/infants. See *DTaP vaccine*.  
 combinations with IPV, HepB, and Hib, 382t-386t  
 contraindications/precautions, 275-278  
 CPT and ICD-9-CM codes, 136t  
 efficacy/immunogenicity/immunogenicity, 271-275  
 handling, 112t  
 nomenclature, 470t  
 recommendations for general use, 278-280  
 safety, 275-278  
 toxoid-containing, reactogenicity and, 162
- Diphtheria and Tetanus Toxoids Adsorbed USP (for Pediatric Use; DT), 276t-277t  
 toxoid, cost of (purchase price), 151t
- Diseases. See also *specific diseases*.  
 vaccination goals for, 44t  
 vaccine-preventable. See *Vaccine-preventable diseases*.  
 for which vaccines are no longer available in the United States, 454t
- Doses of vaccine  
 expired or damaged, 163  
 multidose series, administration of, 157  
 partial or fractional, 156-157  
 reactogenicity from too many, 162
- Drug Listing Act of 1972, 133
- Dryvax (smallpox vaccine), 431-434  
 CPT and ICD-9-CM codes, 139t  
 efficacy/immunogenicity, 437  
 safety, 437
- DT (diphtheria, tetanus toxoids), 276t-277t  
 contraindications/precautions, 169t, 275, 278
- DTaP vaccine, 272t-274t. See also *Daptacel*; *Infanrix*; *Tripedia*.  
 in combination, 382t-386t, 388t-391t  
 contraindications/precautions, 167, 169t, 275, 278  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t, 148t  
 efficacy/immunogenicity, 271-272  
 handling and storage, 112t, 274t  
 minimum ages and intervals for, 158t  
 NIS survey of coverage, 59  
 recommendations for general use, 278-280, 282t-283t  
 safety, 275-278  
 schedule for, 273t  
 catch-up, children age 4 months-6 years, 185t  
 children, age 0-6 years, 180t  
 children, age 7-18 years (Tdap), 183t  
 shortages of, recent, 78t
- DTwP vaccine, 379
- Dukoral, 454t
- E coli*, bioterrorism potential, 82t-83t
- Eczema, as contraindication for vaccination, 172t, 438
- Education on immunizations, 121-122
- Effectiveness, monitoring, 62
- Efficacy, 37. See also *Correlates of protection*; *specific vaccines*.
- Eggs, allergy to, 171t, 173t, 174t, 323-324, 451
- Elimination of disease, 44-45, 44t
- Embryonic cells, use in vaccine production, 252-253
- Emergencies, dealing with, 130-131, 132t-133t
- Emergencies, weather, vaccine handling and, 117t
- Emerging Infections Program Network (CDC), 62
- Emerging infectious diseases, bioterrorism potential, 83t
- EMLA cream, 127
- Encephalitis  
 equine, bioterrorism potential, 83t  
 following MMR, 65  
 following yellow fever vaccine, 174t  
 Japanese. See *Japanese encephalitis*.  
 postvaccination, 450, 452  
 viral, bioterrorism potential, 83t
- Encephalopathy  
 concerns about, 249-251  
 as vaccine contraindication, 167, 169t, 173t, 275
- Engerix-B (HepB), 298t-300t  
 cost of (purchase price), 150t  
 CPT and ICD-9-CM codes, 137t  
 efficacy/immunogenicity, 296
- Engineered agents, 14t-15t, 18
- Engineered antibodies, 19
- Engineered attenuation, 16-17
- Enterotoxin B, bioterrorism potential, 83t
- Enterotoxin, diphtheria, 267
- Epidemiology and Prevention of Vaccine-Preventable Diseases ("Pink Book")*,  
 viii-ix, 57, 462
- Epitopes, 19
- Epsilon toxin, bioterrorism potential and US vaccine status, 82t
- Equine encephalitis, bioterrorism potential, 83t
- Eradication of disease, 43, 44t
- Escherichia coli*, bioterrorism potential, 82t-83t
- Every Child by Two (ECBT), 461
- Excipients, 167, 379. See also *specific vaccines*.
- Exemptions from school immunization requirements, 108
- Extinction of disease, 43-44, 44t, 45
- Extrafollicular reaction, 24-25, 24
- Eye disease, inflammatory, as precaution for vaccination, 172t
- FDA. See *Food and Drug Administration (FDA)*.
- Febrile multiple organ-system failure, 451
- Federal requirements regarding vaccination, 104t-105t
- Fetal bovine serum, 256
- Fetal tissue, use in vaccine production, 252-253

Fever  
 as contraindication, 169t, 278  
 dealing with, 127

Filamentous hemagglutinin (FHA), 267, 272t

Fimbriae (FIM), 267, 272t

Financing, 67-74  
 IOM report on, 73-74  
 NVAC suggestions on, 74  
 public/private sector participation in, 67-73, 71  
 purchase price of vaccines, 134-135, 149t-152t  
 of routine childhood vaccinations, 70t  
 state financing models, 73-74, 73

Flebogamma DIF 5% (immune globulin, human, IV), 141t

Fluarix (TIV, influenza, split virus), 316t-320t  
 cost of (purchase price), 152t  
 CPT and ICD-9-CM codes, 137t

Flulaval (TIV, influenza, split virus), 137t, 316t-320t

Flumist (LAIV, live influenza, intranasal), 138t, 316t-320t

Fluvirin (TIV, influenza, split virus), 316t-320t  
 cost of (purchase price), 152t  
 CPT and ICD-9-CM codes, 137t

Fluzone (TIV, influenza, split virus), 316t-320t  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 137t

Food and Drug Administration (FDA), 56, 459

Food handlers, vaccination of, 221t, 294

Food safety threats, bioterrorism potential, 82t

Foresters, vaccination of, 221t

*Francisella tularensis*, 82t

Freezers, general rules regarding, 111-116

FUTURE (Females United to Unilaterally Reduce Endo/Ectocervical Disease)  
 I and II, 309

GABHS (group A beta-hemolytic streptococcus), 365

GamaSTAN S/D (immune globulin, human, IM), 140t

Gamimune N (immune globulin, human, IV), 141t

Gammagard Liquid (immune globulin, human, IV), 140t

Gammagard S/D (immune globulin, human, IV), 140t

Gammar-P.I.V. (immune globulin, human, IV), 140t

Gamunex (immune globulin, human, IV), 141t

Gardasil (HPV4), 309-312, 310t  
 cost of (purchase price), 150t  
 CPT and ICD-9-CM codes, 137t  
 efficacy/immunogenicity, 309-311  
 licensure and background on, 308-309  
 recommendations for general use, 312  
 safety, 311-312

Gelatin, 256. See also *specific vaccines*.  
 allergy to, 171t, 174t

Genital warts, 307

Germinal center reaction, 25-31, 27

Germline antibodies, 24, 24

GI disease, as contraindication/precaution, 172t

Glanders, bioterrorism potential, 83t

Global Alliance for Vaccines and Immunization (GAVI), 461

Gloves, not routinely needed, 166

Gluteal muscle, avoidance in IM injections, 163

Goals of immunization programs, 43-45, 44t

Governmental agencies and committees, 55, 56, 459-460

Grace period  
 for age requirements, 108  
 for vaccine intervals, 156

Group A beta-hemolytic streptococcus (GABHS), 365

Guillain-Barré syndrome, 251-252  
 as contraindication/precaution  
 for anthrax vaccination, 408  
 for diphtheria, tetanus, and pertussis vaccines, 169t, 173t, 278  
 for influenza vaccines, 323-324  
 for LAIV, 171t  
 for MCV4, 342  
 hepatitis A and, 285

Gulf War Syndrome, 408

*Haemophilus influenzae* type b (Hib), 280-284. See also *Influenza*.  
 clinical features, 281  
 diabetes and, 254, 255  
 epidemiology and transmission, 281  
*Healthy People 2010* objectives for, 92t  
 herd immunity and, 281  
 morbidity and mortality from, 46t  
 newborns, relative protection against, 18  
 pathogen, 280  
 polysaccharide component, 17  
 reservoir of infection, 40  
 vaccines for, 286t-287t  
 background on immunization program, 281-284  
 combination, 382t-386t, 388t-391t  
 contraindications/precautions, 170t, 284  
 cost of (purchase price), 150t  
 CPT and ICD-9-CM codes, 137t, 148t  
 efficacy/immunogenicity, 284  
 handling and storage, 112t, 287t  
 impaired immunity, patients with, 193  
 minimum ages and intervals for, 158t  
 nomenclature, 470t  
 recommendations for general use, 284  
 reportable events, 101t  
 safety, 284  
 schedule for, 284, 286t  
 catch-up, children age 4 months-6 years, 185t  
 children, age 0-6 years, 180t  
 shortages of, recent, 78t

Handling and storage of vaccines, 111-116, 112t-115t, 117t

Hantavirus, bioterrorism potential, 83t

Havrix (HepA), 290t-291t  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t  
 efficacy/immunogenicity, 289

- HBIG. See *Hepatitis B immune globulin (HBIG)*.
- HCP. See *Health care personnel*.
- HDVC. See *Imovax Rabies*.
- Health care personnel (HCP), 211-214  
 needlestick injuries and blood exposure, 102-107  
 vaccination recommendations, 94, 102, 106, 107, 211-214, 301, 325, 333, 347, 441
- Healthcare Effectiveness Data and Information Set (HEDIS), 61-62, 461
- Healthy People 2010*, 87-88, 90t-93t  
 adolescents, coverage in 2006, 60  
 general objectives, 90t-91t  
 kindergarten children, coverage in 2006-2007, 61  
 specific objectives, 92t-93t
- Healthy People 2020*, 88
- HEDIS. See *Healthcare Effectiveness Data and Information Set*.
- Helper T lymphocytes (Th cells), 26-28, 27
- Hemagglutinin (HA/H), 313, 319t, 321
- Hematopoietic stem cell transplantation (HSCT), 203  
 revaccination of HSCT patients, 204t-205t
- Hemorrhagic fevers, viral, 82t
- HepaGam B (hepatitis B immune globulin), 303  
 CPT and ICD-9-CM codes, 141t
- Hepatitis A, 285-294  
 clinical features, 285  
 epidemiology and transmission, 285-288  
*Healthy People 2010* objectives for, 92t  
 herd immunity in Butte County, California, 40, 41  
 immune globulin for, 18, 293  
 morbidity and mortality from, 46t  
 nomenclature, 470t  
 pathogen, 285  
 vaccines for, 290t-291t  
 age for, 156  
 background on immunization program, 288-289  
 combination, 388t-391t  
 contraindications/precautions, 170t, 292  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t  
 efficacy/immunogenicity, 289  
 handling and storage, 112t, 291t  
 herd immunity and, 40, 41, 289  
 minimum ages and intervals for, 159t  
 recommendations for use, 292-294  
 during pregnancy, 207  
 postexposure prophylaxis, 293-294  
 pre-exposure prophylaxis, 292-293  
 for travel in endemic areas, 215, 292  
 universal childhood immunization, 45-46, 289  
 safety, 292  
 schedule for, 291t, 299t  
 adults, by age, 189t  
 adults, by medical condition/indication, 191t  
 catch-up, children age 4 months-6 years, 186t  
 catch-up, children age 7-18 years, 187t
- Hepatitis A, vaccines for, schedule for (*continued*)  
 children, age 0-6 years, 180t  
 children, age 7-18 years, 183t  
 shortages of, recent, 78t
- Hepatitis B, 294-303  
 clinical features, 294-295  
 epidemiology and transmission, 295  
 HBsAg/HBsAb, 17, 294-295, 301-302, 303  
*Healthy People 2010* objectives for, 92t  
 immune globulin for, 18  
 morbidity and mortality from, 46t  
 nomenclature, 470t  
 pathogen, 294  
 vaccines for, 17, 298t-300t. See also *specific vaccines*.  
 background on immunization program, 295-296  
 combination, 382t-386t, 388t-391t  
 contraindications/precautions, 170t, 297  
 cost of (purchase price), 149t-150t  
 CPT and ICD-9-CM codes, 136t-137t, 148t  
 efficacy/immunogenicity, 296-297  
 minimum ages and intervals for, 158t  
 recommendations for use, 297-303  
 adult vaccination, 301-302  
 during pregnancy, 206-207  
 for health care personnel, 102, 106, 107, 212-213  
 for nonoccupational exposures, 306t  
 for occupational exposures, 304t-305t  
 postexposure prophylaxis, 296, 302-303  
 for travel, 215, 301  
 universal infant, child and adolescent immunization, 297-301
- reportable events, 101t  
 safety, 68t, 297  
 schedule for  
 adults, by age, 189t  
 adults, by medical condition/indication, 191t  
 catch-up, children age 4 months-6 years, 185t  
 catch-up, children age 7-18 years, 187t  
 children, age 0-6 years, 180t  
 children, age 7-18 years, 183t  
 site of administration, 163  
 storage, 299t
- Hepatitis B immune globulin (HBIG)  
 contraindications, 303  
 CPT and ICD-9-CM codes, 141t  
 interval for receipt of live vaccines after, 165t  
 recommendations for use, 303  
 for exposed neonates, 296, 302-303  
 for nonoccupational exposures, 306t  
 for occupational exposures, 304t-305t  
 safety, 303  
 schedule for, 183t
- Hepatitis B surface antigen/antibody (HBsAg/HBsAb), 294-295, 301-302, 303
- Herd immunity, 39-43, 41-42
- Herpes simplex virus, 373

Herpes zoster (shingles), 364, 365-366, 373-378. See also *Zoster (herpes zoster; shingles)*.

Heterologous host, 16

Heterologous infections, 240

Heuristic thinking about vaccines, 225-227

Hib. See *Haemophilus influenzae type b*.

HIV. See *Human immunodeficiency virus (HIV)*.

Hooper, Edward, 257

HPV. See *Human papillomavirus (HPV)*.

HPV4. See *Human papillomavirus (HPV), vaccines for*.

HRV. See *Rotavirus, vaccines for, human (HRV)*.

HSCT. See *Hematopoietic stem cell transplantation*.

Human immunodeficiency virus (HIV)

- CD4 counts and, 194, 201-203, 202t
- impaired immunity and, 200-203
- infected individuals
  - hepatitis B vaccination, 301
  - immune globulin for immunoprophylaxis in, 196, 335
  - MMR vaccination, 194
  - N meningitidis* vaccination, 343
  - S pneumoniae* vaccination, 361
  - tetanus immune globulin for at-risk children, 196
  - vaccination issues, 200-203
  - varicella vaccination, 371
  - yellow fever vaccination, 452
- infection as contraindication for vaccination, 173t
- polio vaccine, concerns about AIDS causation by, 257
- postexposure prophylaxis, 107

Human papillomavirus (HPV), 303-312

- clinical features, 307-308
- epidemiology and transmission, 308
- nomenclature, 470t
- pathogen, 303-307
- vaccine candidate for (bivalent HPV vaccine, Cervarix), 137t, 312
- vaccine for (HPV4), 308-309, 310t
  - background on immunization program, 308-309
  - contraindications/precautions, 170t, 312
  - cost of (purchase price), 150t
  - CPT and ICD-9-CM codes, 137t
  - efficacy/immunogenicity, 309-311
  - handling and storage, 113t, 310t
  - minimum ages and intervals for, 160t
  - recommendations for use, 312
  - safety, 311-312
  - schedule for, 310t, 312
    - adults, by age, 189t
    - adults, by medical condition/indication, 191t
    - catch-up, children age 7-18 years, 187t
    - females age 7-18 years, 183t, 308-309, 312

Human rabies immune globulin (HRIG). See *Rabies immune globulin, human*.

Human rotavirus vaccine. See *Rotavirus, vaccines for, human (HRV)*.

Humoral deficiencies, 197

Hygiene hypothesis, 253

HyperHEP B S/D (hepatitis B immune globulin, human), 141t

Hyperimmune globulins, in passive immunization, 18-19

HyperRAB S/D (rabies immune globulin, human), 141t, 419

HyperTET (tetanus immune globulin), 141t

ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes, 133, 148t

- for preventive medicine services, 134t
- for vaccines and immune globulins, 136t-142t

IGIM. See *Immune globulin, intramuscular (IGIM)*.

Illegal drug users, vaccination of, 221t

Immigrants, vaccination policies on, 210-211

Immune globulin, 18-19. See also *specific immune globulins*.

- administration, CPT codes for, 147t
- hyperimmune globulins, 18-19
  - as immunoprophylaxis in immunocompromised individuals, 196
  - intervals for vaccination with live vaccines and, 164t-165t
  - intramuscular (IGIM), CPT and ICD-9-CM codes, 140t-142t
  - intravenous (IGIV)
    - administration, 127
    - CPT and ICD-9-CM codes, 140t-141t
  - isotypes, 23
  - polyclonal, passive immunization with, 18

Immune memory, 25, 28, 30-31

Immune response, 19-37

- adaptive immune system, 19, 25-28
- anamnestic response, 28, 29, 30-31
- antibodies, 19-25
  - genetic determinants of responses, 31
  - germline, 24, 24
  - persistence of, 30-31
- antigens, 19-23
- cytotoxic T cells (Tc cells), 26, 31-37, 34
- extrafollicular reaction, 24-25, 24
- germinal center reaction, 25-31, 27
- homotypic vs heterotypic, 30
- hygiene hypothesis, 253
- innate immune system, 25
  - stimulating, 28
- multiple immunizations and, 68t, 238-240
- priming and boosting, 28-29, 29
- suboptimal, in impaired immunity, 194
- T-independent antigens and responses, 25
- time course of, 28-31, 29

Immunity

- criteria for (specific diseases), 334t, 371t
- impaired. See *Impaired immunity*.
- testing for, 166, 212-213
- waning, 239, 271, 365

Immunization, 13-19. See also *Administration of vaccines; Immune response*.

- active, 13-18
- attenuation of vaccines, 13-18
- booster, 29, 29
- correlates of protection, 37-39
- costs-benefit analysis, 47, 48t

## Immunization (continued)

- defined, 13
  - education on, 121-122
  - emergencies, dealing with, 130-131, 132t-133t
  - exemptions from school immunization requirements, 108
  - financing, 67-74, 70t, 71
  - goals of, 43-45, 44t
  - herd immunity, 39-43, 42-43
  - monitoring delivery (coverage and timeliness), 58-62
  - monitoring effectiveness, 62
  - multiple vaccines, simultaneous administration, 94, 238-240
  - natural infection and, 237-238
  - passive, 13, 18-19
  - primary, 28-29, 29
  - priming and boosting, 28-29, 29
  - public health impact of, viii, 45-47, 46t, 48t, 237
  - reactions to. *See Adverse events.*
  - registries for (IISs), 119-121, 120t
  - rules for (general recommendations), 57
  - schedules, 179, 180t-192t. *See also Schedules for routine immunizations.*
  - school mandates and state legislation regarding, 107-108
  - screening for, 122, 124t-125t
  - in special circumstances. *See Special circumstances.*
  - standards and regulations, 87-100. *See also Standards, principles, and regulations.*
    - adult, 95-96, 96t
    - Healthy People 2010* goals, 87-88, 90t-93t
    - pediatric, 88-95
    - waiting period after, 130
- Immunization Action Coalition (IAC), 461
- Immunization Information Systems (IISs; formerly, Registries), 119-121, 120t
- Immunization Safety Review Committee (ISRC), 66, 68t-69t
- Immunocompromised states. *See Impaired immunity.*
- Immunogenicity, 31, 37, 238. *See also specific vaccines.*
- Immunosuppressive therapy, as precaution for vaccination, 172t, 422, 438
- Imovax Rabies-HT (rabies immune globulin, human, heat-treated), 141t, 419-422
- Imovax Rabies (HDCV), 420t-421t
- CPT and ICD-9-CM codes, 139t
  - safety, 422
- Impaired immunity, 193-203
- CD4 counts, 194, 201-203, 202t
  - close contacts, immunization of, 194-195, 195t
  - as contraindication/precaution, 172t-174t, 438
  - herpes zoster and, 365-366
  - HIV infection and, 200-203, 202t, 335
  - immune globulin, for measles exposure, 335
  - live vaccines
    - contraindications/precautions for, 167, 195, 196-197, 198, 331, 354
    - immunization of close contacts, 195, 195t
  - official recommendations vs product labeling, 195-196
  - passive immunoprophylaxis and, 196
  - qualitative differences in, 193-194
  - quantitative differences in, 194
  - risk-benefit balance of vaccination, 193

## Impaired immunity (continued)

- S pneumoniae* vaccination and, 361
  - specific states other than HIV infection, 196-200
  - asplenia, anatomic and functional, 199-200
  - chemotherapy and solid organ transplantation, 198-199
  - chronic disease, 200
  - complement deficiencies, 193-194, 197-198
  - defects of cell-mediated immunity, 197
  - hematopoietic stem cell transplantation and leukemia, 203, 204t-205t
  - humoral deficiencies, 193, 197
  - phagocyte disorders, 197
  - steroids and, 198
  - suboptimal immune response in, 194
  - vaccine contraindications/precautions, 193, 194, 195-196
  - vaccine recommendations and considerations, 196-200
- Inactivated vaccines, 14t-15t, 17-18, 20t-22t
- intervals for vaccination, 155-156
  - specificity of, 29-30
- Infanrix (DTaP), 272t-274t
- cost of (purchase price), 149t
  - CPT and ICD-9-CM codes, 136t
  - efficacy of, 271-272
- Infants
- hepatitis B vaccination for, 296, 302-303
  - preterm and low birth weight, 207-210
  - rotavirus vaccination for, 354-355
- Infection
- control, elimination, eradication, and extinction of agents, 44, 44t
  - exposure to, herd immunity and, 39-40
  - preventing, 18, 23, 30-31, 35
  - preventing vs limiting, 35-36
  - reservoirs of, 40
- Infectious Diseases Society of America (IDSA), 460
- Influenza, 312-326
- A, B, and C, 313, 316t, 321. *See also Influenza A (H5N1).*
  - clinical features, 313-314
  - cost-benefit of vaccination for, 315
  - epidemiology and transmission, 314
  - nomenclature, 470t
  - pathogen, 312-313
  - vaccines for, 316t-320t
    - background on immunization program, 315
    - combination, 379
    - contraindications/precautions, 171t, 323-324, 325
    - cost of (purchase price), 150t-151t
    - coverage rate for adults, 61
    - CPT and ICD-9-CM codes, 137t-138t
    - efficacy/immunogenicity, 315-322
    - Guillain-Barré syndrome and, 251, 324
    - health care workers, vaccination of, 213-214
    - LAIV (live-attenuated), 316t-320t
      - attenuation of, 16-17
      - contraindications/precautions, 171t, 323-324, 325
      - cost of (purchase price), 150t

- Influenza, vaccines, LAIV (live-attenuated) (*continued*)
- efficacy/immunogenicity, 321-322
  - handling, 113t
  - interval for receipt of antibody-containing products, 164t-165t
  - minimum ages and intervals for, 159t
  - safety, 323-324
  - schedule for, 191t
  - recommendations for use, 324-326
    - for travel, 215
  - safety, 69t, 322-324
  - schedule for, 319t
    - adults, by age, 189t
    - adults, by medical condition or indication, 191t
    - children, age 0-6 years, 180t
    - children, age 7-18 years, 183t
  - shortages of, recent, 75, 78t-79t
  - storage, 319t-320t
  - TIV (trivalent inactivated influenza virus vaccine), 316t-320t
    - contraindications/precautions, 173t, 323
    - cost of (purchase price), 151t-152t
    - CPT and ICD-9-CM codes, 137t
    - efficacy/immunogenicity, 321
    - handling, 114t
    - minimum ages and intervals for, 159t
    - safety, 322-323
    - schedule for, 191t
- Influenza A (H5N1), 410-412
- clinical features, 410
  - epidemiology and transmission, 410-411
  - pathogen, 410
  - vaccines for, 411-412, 412t
    - efficacy/immunogenicity, 411
    - recommendations, 412
    - safety, 411-412
- Injection site hypersensitivity, 63-64
- Injection techniques and sites, 123, 126, 128t-129t
- Injury. See *National Childhood Vaccine Injury Act; Vaccine Injury Compensation Program (VICP)*.
- Innate immune system, 25
- Innate immunity, stimulating, 28
- Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, 461
- Institute of Medicine (IOM), 63t
  - Immunization Safety Review Committee of, 66, 68t-69t
    - report on vaccine financing, 73-74
- International adoptees, refugees, and immigrants, 210-211
- International agencies, 460
- Intervals for vaccinations, 158t-161t
  - definition of, x
  - grace period, 156
  - live vaccines, 155
    - between live vaccines and antibody-containing products, 164t-165t
    - minimum, 156, 158t-161t
    - simultaneous administration, 155
- Intradermal administration (smallpox vaccine), 123
- Intramuscular (IM) administration of vaccines, 123, 126
  - gluteal muscle, avoidance of, 163
  - preferred sites and needle length, 128t-129t
- Intramuscular immune globulin (IGIM). See *Immune globulin, intramuscular (IGIM)*.
- Intranasal administration of vaccines, 126-127
- Intravenous immune globulin (IVIG). See *Immune globulin, intravenous (IVIG)*.
- Intussusception
  - history of, as a precaution for vaccination, 172t, 354
    - RRV-TV and, 66-67, 101t, 349
- IOM. See *Institute of Medicine*.
- IPOL (IPV), 346t. See also *Polio, vaccines for*.
  - cost of (purchase price), 150t
    - CPT and ICD-9-CM codes, 138t
- IPV. See *Polio, vaccines for*.
- Isotype switching, 28
- ISRC. See *Immunization Safety Review Committee*.
- Iveegam E/N (immune globulin, human, IV), CPT and ICD-9-CM codes, 140t
- IVIG. See *Immune globulin, intravenous (IGIV)*.
- Japanese encephalitis, 413-417
  - clinical features, 413
  - epidemiology and transmission, 413-414
  - nomenclature, 470t
  - pathogen (Japanese encephalitis virus; JEV), 413
  - vaccines for, 415t
    - background on immunization program, 414
    - contraindications/precautions, 170t, 416
    - CPT and ICD-9-CM codes, 138t
    - efficacy/immunogenicity, 414-415
    - recommendations, 416-417
    - safety, 415-416
- JE-Vax (Japanese encephalitis vaccine), 138t, 414-417, 415t
- JEV (Japanese encephalitis virus). See *Japanese encephalitis*.
- Kawasaki disease, 54
- Kinrix (DTaP-IPV), 382t-386t
  - CPT and ICD-9-CM codes, 136t
- Laboratory workers, vaccination of, 221t, 292, 347, 417, 424t, 440, 441, 445, 451
- LAIV (live-attenuated influenza vaccine), 316t-320t, 321-322. See also *Influenza, vaccines for, LAIV (live-attenuated)*.
- Latex, 167, 409. See also *specific vaccines*.
- Leukemia, impaired immunity and, 203
- Liability issues. See *National Childhood Vaccine Injury Act; National Vaccine Injury Compensation Program*.
- Licensure. See *Vaccine development and licensure*.
- Live-attenuated influenza vaccine. See *LAIV*.
- Live vaccines, 13-17
  - in combination, viral interference and, 379
  - contraindications, 167
  - impaired immunity and, 167, 195, 196-197, 198
  - intervals for receipt of antibody-containing products, 162-163, 164t-165t
  - intervals for vaccination, 155

- Live vaccines (*continued*)  
 pregnancy and, 167, 206, 208t-209t  
 vs inactivated vaccines, 14t-15t, 20t-22t, 36
- Liver damage. See *Hepatitis A*; *Hepatitis B*.
- Local anesthetics, 127
- Low birth weight infants, 207-210  
 hepatitis B vaccination and, 297-301
- Lyme disease, 454t
- LYMERix, 454t
- M-M-R II (MMR). See also *MMR vaccines*.  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 138t
- Macrophages, 26
- Mad cow disease (MCD), vaccines and, 254-256
- Major histocompatibility complex (MHC), 31  
 class I molecules (MHC-I), 31-35, 34  
 class II molecules (MHC-II), 26, 34
- Manufacturers of vaccines, web site information, 462-463
- Marketing claims, package insert and, 54
- MCV4, 340t-341t. See also *Neisseria meningitidis*.  
 contraindications/precautions, 171t, 342  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 138t  
 efficacy/immunogenicity, 339-342  
 Guillain-Barré syndrome and, 251-252, 342  
 handling and storage, 113t, 342t  
 intervals for vaccination, 155-156  
 licensure of, 39, 339  
 minimum ages and intervals for, 159t  
 recommendations for general use, 342-343  
 safety, 342  
 schedule for  
   adults, by age, 189t  
   adults, by medical condition/indication, 191t  
   children, age 0-6 years, 180t  
   children, age 7-18 years, 183t  
 shortages of, recent, 75, 79t
- Measles, 326-335  
 clinical features, 327  
 criteria for immunity, 334t  
 epidemiology and transmission, 328-329  
*Healthy People 2010* objectives for, 92t  
 immune globulin for prevention of, 18  
 lack of reservoir of infection, 40  
 morbidity and mortality from, 46t  
 nomenclature, 470t  
 pathogen, 326  
 vaccines for, 332t-333t. See also *MMR vaccines*.  
   background on immunization program, 329-330  
   combination, 330, 388t-391t  
   CPT and ICD-9-CM codes, 138t  
   efficacy/immunogenicity, 330  
   recommendations for use, 333-335
- Measles, vaccines for (*continued*)  
 reportable events, 100t  
 safety, 331-333
- Medicaid  
 Centers for Medicare & Medicaid Services (CMS), 459  
 coverage rates for combination vaccines, 387  
 coverage surveys of participants, 61  
 vaccine financing and, 70
- Medicare  
 Centers for Medicare & Medicaid Services (CMS), 459  
 vaccine financing and, 70
- Melioidosis, bioterrorism potential, 83t
- Membrane attack complex, 23
- Memory. See *Immune memory*.
- Men who have sex with men, vaccination of, 221t, 292, 301
- Menactra (MCV4), 340t-341t  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 138t
- Meningitis, 336, 337. See also *Neisseria meningitidis*.  
 anthrax and, 405  
 bacterial, 355, 356  
   *Healthy People 2010* objectives for, 92t  
 Hib and, 281
- Meningococcal polysaccharide conjugate vaccine, 4-valent. See *MPSV4*.
- Meningococemia*, 336
- Meningococcus. See *Neisseria meningitidis*.
- Menomune-A/C/Y/W-135 (MPSV4), 340t-341t  
 CPT and ICD-9-CM codes, 138t
- Mercury in vaccines/thimerosal, 245-249
- Meruvax II (rubella, live, SC), CPT and ICD-9-CM codes, 139t
- MHC, MHC-I, MHC-II. See *Major histocompatibility complex*.
- Military personnel, vaccination of, 221t, 342, 370, 407, 409-410, 438, 443
- Missed opportunities, 118  
 erroneous contraindications and, 168
- Mix-ups, vaccine, and how to handle them, 163-166
- MMR vaccines  
 autism and, 68t, 69t, 240-243, 242  
 background on immunization program, 329-330  
 in combination, 330  
 contraindications/precautions, 171t, 331-333  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 138t  
 efficacy/immunogenicity, 330-331  
 handling and storage, 113t, 332t  
 impaired immunity patients and, 196, 197, 199  
 interval for receipt of antibody-containing products, 164t-165t  
 minimum ages and intervals for, 159t  
 recommendations for general use, 333-335  
 reportable events, 100t  
 safety, 68t, 69t, 331-333  
 schedule for, 332t, 333  
   adults, by age, 189t  
   adults, by medical condition/indication, 191t  
   catch-up, children age 4 months-6 years, 185t

- MMR vaccines, schedule for (*continued*)  
 catch-up, children age 7-18 years, 183t, 187t  
 children, age 0-6 years, 180t, 333  
 children, age 7-18 years, 183t  
 health care personnel, 212
- MMRV vaccine, 388t-391t  
 contraindications/precautions, 196  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 138t  
 handling, 113t  
 interval for receipt of antibody-containing products, 164t-165t  
 shortages of, recent, 75, 79t
- Monitoring  
 for adverse events. See *Vaccine Adverse Event Reporting System*.  
 for vaccine delivery (coverage and timeliness), 58-62  
 for vaccine effectiveness, 62
- Monocytes, 25
- Month(s), definition of, x
- Morbidity and mortality from vaccine-preventable diseases, 46t, 48t, 95
- Morticians, vaccination of, 221t
- MPSV4 (meningococcal polysaccharide conjugate vaccine, 4-valent), 340t-341t  
 contraindications/precautions, 171t, 342  
 CPT and ICD-9-CM codes, 138t  
 efficacy/immunogenicity, 338-339  
 handling and storage, 113t, 342t  
 minimum ages and intervals for, 159t  
 recommendations for general use, 342-343  
 safety, 342  
 schedule for, 191t
- Multiple sclerosis, vaccines and, 252
- Mumps, 326-335  
 clinical features, 327-328  
 criteria for immunity, 334t  
 epidemiology and transmission, 329  
*Healthy People 2010* objectives for, 92t  
 morbidity and mortality from, 46t  
 nomenclature, 470t  
 pathogen, 326  
 resurgence of, 45  
 vaccines for, 332t-333t. See also *MMR vaccines*.  
 background on immunization program, 329-330  
 combination, 330, 388t-391t  
 CPT and ICD-9-CM codes, 138t  
 efficacy/immunogenicity, 330  
 recommendations for use, 333-335  
 safety, 331-333
- Mumps vaccine (mumps, live), CPT and ICD-9-CM codes, 138t
- Mycobacterium tuberculosis*, 454t, 471t
- Myopericarditis, 65
- Nabi-HB (hepatitis B immune globulin), 303  
 CPT and ICD-9-CM codes, 141t
- National Center for Immunization and Respiratory Diseases (NCIRD), 55, 56, 62, 459
- National Childhood Encephalopathy Study (NCES; UK), 250
- National Childhood Vaccine Injury Act, 65, 96-102
- National Coalition for Adult Immunization, 95
- National Drug Codes (NDCs), 133-134
- National Foundation for Infectious Diseases (NFID), 461
- National Health Interview Survey (NHIS), 60, 461
- National Immunization Survey (NIS), 58-60, 59
- National Institutes of Health (NIH), agencies and committees, 56, 459
- National Network for Immunization Information (NNii), 461
- National Notifiable Disease Surveillance System (NNDS), 62, 461
- National Vaccine Advisory Committee (NVAC), 55, 56, 58, 459  
 Initiative on Immunization Registries, 119-121  
 pediatric immunization standards, 88-95
- National Vaccine Injury Compensation Program (VICP), 56, 94, 97-98, 459
- National Vaccine Plan, 58
- National Vaccine Program Office (NVPO), 58, 459
- Native Americans and Alaskans, vaccination of, 221t
- NCDs (National Drug Codes), 133-134
- NCIRD. See *National Center for Immunization and Respiratory Diseases*.
- Needlestick injuries, 102-106
- Negri bodies, 417
- Neisseria meningitidis*, 17, 335-343, 470t  
 clinical features, 335-336  
 epidemiology and transmission, 336  
*Healthy People 2010* objectives for, 92t  
 nomenclature, 470t  
 pathogen, 335  
 prevention of, 30  
 serogroups, 336  
 vaccines for, 340t-341t  
 background on immunization program, 337-338  
 contraindications/precautions, 171t  
 cost-benefit analysis of, 337  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 138t  
 efficacy/immunogenicity, 338-342  
 immunocompromised individuals and, 193, 198  
 recommendations for use, 193, 198, 342-343  
 for travel, 216
- Neomycin, allergy to, 171t, 174t
- Neuraminidase (NA/N), 313
- Neurologic disorder, progressive, as contraindication, 169t, 173t
- Neurotropic disease, vaccine-associated, 450
- Neutralization of viruses/toxins, 23
- New Vaccines Surveillance Network (NVS), 62
- Nipah virus, bioterrorism potential, 83t
- NIS. See *National Immunization Survey*.
- NNDS. See *National Notifiable Disease Surveillance System*.
- Nomenclature, 470t-471t  
 combination vaccines, x  
 goals of immunization programs, 44t  
 immunization and vaccination, 13  
 reconstituted vaccines, x
- NVAC. See *National Vaccine Advisory Committee*.

NVPO. See *National Vaccine Program Office*.  
NVSN. See *New Vaccines Surveillance Network*.

Observation period after vaccination, 130  
Occupational Safety and Health Administration (OSHA), 102-107  
Octagam (immune globulin, human, IV), 141t  
Office of General Counsel (OGC), 460  
Office supplies for emergency situations, 132t-133t  
Office visit, routine, at 6 months, codes for, 148t  
Omnibus Budget Reconciliation Act, 70  
Opsonization, 23  
OPV. See *Polio, vaccines for*.  
Oral administration of vaccines, 123-126  
Orochol, 454t  
OSHA. See *Occupational Safety and Health Administration*.  
Otitis media, acute, 355, 356, 357

Package insert (PI), 53-54  
Pain, dealing with, 127  
Palivizumab (RSV-mAb), 147t  
Pan American Health Organization (PAHO), 460  
Panglobulin NF (immune globulin, human, IV), 140t  
Parent phenotypes regarding vaccination, 229t  
Parents of Kids With Infectious Diseases (PKID), 461  
Passive immunization, 13, 18-19  
Pathogen-specific molecular patterns, 25  
PCECV. See *RabAvert*.  
PCV7. See *Pneumococcal vaccines, PCV7*.  
Pediarix (DTaP-HepB-IPV), 382t-386t  
    cost of (purchase price), 149t  
    CPT and ICD-9-CM codes, 136t  
    schedule for, 297  
Pediatric immunization practices  
    CPT codes for, 144t-145t  
    standards for, 88-95  
Pediatric Infectious Diseases Society (PIDS), 460  
PedvaxHIB (PRP-OMPC), 284, 286t-287t  
    cost of (purchase price), 150t  
    CPT and ICD-9-CM codes, 137t  
    efficacy/immunogenicity, 284  
Pentacel (DTaP-IPV/Hib), 382t-386t  
    CPT and ICD-9-CM codes, 136t  
Pentavalent rotavirus vaccine (PRV). See *Rotateq (PRV)*.  
Peractin (PRN), 267, 272t  
Pertussis, 267-280  
    clinical features, 268-269  
    epidemiology and transmission, 269-270  
    *Healthy People 2010* objectives for, 92t  
    morbidity and mortality from, 46t  
    pathogen, 267-268  
    resurgence of, 45, 46t  
    toxin (PT), 267-268  
    vaccines for, 17, 272t-274t  
        acellular, 39, 271

Pertussis, vaccines for (*continued*)  
    adult. See *Tdap vaccine*.  
    background on immunization program, 271  
    brain damage and, 249-251  
    children/infants. See *DTaP vaccine*.  
    contraindications/precautions, 275-279  
    efficacy/immunogenicity, 271-275  
    recommendations for general use, 278-280  
    reportable events, 100t  
    safety, 275-278  
Phagocyte disorders, in impaired immunity, 197  
Phase 1, 2, 3, and 4 trials, 51-53, 52  
Physical examination, no requirement for, 166  
PI (package insert), 53-54  
*Pink Book (Epidemiology and Prevention of Vaccine-Preventable Diseases)*, viii-ix, 57, 462  
Plague, 82t, 454t  
Pneumococcal vaccines, 357-361. See also *Streptococcus pneumoniae*.  
    PCV7 (pneumococcal conjugate vaccine, 7-valent), 358t-359t  
        contraindications/precautions, 172t, 360  
        cost of (purchase price), 151t  
        CPT and ICD-9-CM codes, 138t, 148t  
        efficacy/immunogenicity, 357-360  
        handling and storage, 114t, 359t  
        herd immunity and, 40-43, 42  
        minimum ages and intervals for, 159t  
        recommendations for general use, 360-364, 362t-363t  
        safety, 360  
        schedule for, 358t, 360-361  
            catch-up, children age 4 months-6 years, 185t  
            children, age 0-6 years, 180t, 362t-363t  
        shortages of, recent, 75, 79t-80t  
    PPSV23 (pneumococcal polysaccharide vaccine, 23-valent), 358t-359t  
        contraindications/precautions, 172t, 360  
        cost of (purchase price), 151t  
        CPT and ICD-9-CM codes, 138t  
        efficacy/immunogenicity, 360  
        handling and storage, 114t, 359t  
        minimum ages and intervals for, 159t  
        number of doses, reactogenicity and, 162  
        recommendations for general use, 360-364, 362t-363t  
            for adults age 65 and over, 215, 360, 361  
        safety, 360  
        schedule for, 358t  
            adults, by age, 189t  
            adults, by medical condition/indication, 191t  
            children, age 0-6 years, 362t-363t  
            children, age 7-18 years, 183t  
Pneumococcus  
    mortality from, 356  
    nomenclature, 470t  
    vaccination against, 221t-222t  
    vaccines, coverage rate for adults, 61  
Pneumonia. See *Streptococcus pneumoniae*.

Pneumovax 23 (PPSV23), 358t-359t. See also *Pneumococcal vaccines*, PPSV23.  
cost of (purchase price), 151t  
CPT and ICD-9-CM codes, 138t  
Policy. See *Vaccine policy*.  
Polio, 343-347  
clinical features, 343-344  
epidemiology and transmission, 344  
eradication initiative, 344-345  
*Healthy People 2010* objectives for, 92t  
last cases in United States, 344  
morbidity and mortality from, 46t  
nomenclature, 470t  
pathogen, 343  
vaccines for, 344-347, 346t  
AIDS pandemic, concerns about, 257  
background on immunization program, 344-345  
cancer and, concerns about, 256-257  
combination, 382t-386t  
contraindications/precautions, 170t, 196, 347  
CPT and ICD-9-CM codes, 138t  
efficacy/immunogenicity, 345  
inactivated (IPV), 346t  
combination vaccines, 382t-386t  
contraindications/precautions, 170t, 196, 347  
cost of (purchase price), 150t  
CPT and ICD-9-CM codes, 138t  
development of, 17  
efficacy/immunogenicity, 345  
handling, 113t  
minimum ages and intervals for, 158t  
reportable events, 101t  
schedule for, 346t, 347  
catch-up, children 7-18 years, 183t, 187t  
catch-up, children age 4 months-6 years, 185t  
children, age 0-6 years, 180t  
children, age 7-18 years, 183t  
oral (OPV)  
efficacy/immunogenicity, 345  
polio infection and, 344  
reportable events, 100t, 223  
recommendations for use, 215, 347  
safety, 347  
serial passage of, 13  
SV40 contamination and, 68t, 256-257  
Poliomyelitis. See *Polio*.  
Polyclonal immune globulin, 18, 19  
Polygam S/D (immune globulin, human, IV), CPT and ICD-9-CM codes, 140t  
Polyribosylribitol phosphate (PRP) antibody, 38  
Polysaccharide vaccines, 17-18, 30  
immune memory, lack of induction of, 25  
protein-polysaccharide vaccines, 18, 31, 32  
advantages of, 33t, 40  
Postherpetic neuralgia (PHN), 365, 373, 374  
Power outages, 117t

PPSV23. See *Pneumococcal vaccines*, PPSV23.  
Precautions. See *Contraindications and precautions*.  
Pregnancy, 203-207  
contraindications and precautions for vaccination during, 167, 170t-171t,  
173t-174t, 206, 208t-209t, 292, 331, 347, 370, 378  
natural immunization of fetus during, 18  
rubella, effects on fetus, 328  
screening for hepatitis B antigen, 302  
smallpox/smallpox vaccination and, 423, 437, 438  
vaccination during, 203-207, 208t-209t  
counseling women about vaccines, 206  
influenza vaccines, 324, 325  
*S pneumoniae* vaccination, 364  
Tdap and Td vaccines, 280  
yellow fever vaccination, 452  
varicella-zoster immune globulin during, 207, 372  
Prescription Drug User Fee Act (PDUFA), 53  
Preservative-free vaccines, 249. See also *specific vaccines*.  
Preterm and low birth weight infants, 207-210  
Prevention of infection. See *Infection, preventing*.  
Prenar (PCV7), 358t-359t. See also *Pneumococcal vaccines*, PCV7.  
cost of (purchase price), 151t  
CPT and ICD-9-CM codes, 138t  
Primary immunization, 28-29, 29  
Primary vaccine failure, 30  
Prions, 254-256  
Privigen (immune globulin, human, IV), 141t  
Probabilistic thinking, 224-225, 224  
Professional associations, 460  
ProQuad (MMRV), 388t-391t  
cost of (purchase price), 151t  
CPT and ICD-9-CM codes, 138t  
Protein-polysaccharide vaccines, 18, 31, 32. See also *specific vaccines*.  
advantages of, 33t, 40  
PRP. See *Polyribosylribitol phosphate (PRP) antibody*.  
PRP-OMPC. See *PedvaxHIB (PRP-OMPC)*.  
PRP-T. See *ActHIB (Hib, PRP-T conjugate)*.  
PRV. See *RotaTeq (PRV)*.  
Psittacosis, bioterrorism potential, 83t  
Public health. See also *Concerns about vaccines, addressing*.  
impact of vaccines and vaccination programs on, viii, 45-47, 46t, 48t, 237  
risks of refusal of vaccination, 223, 230, 232-233, 238  
Public safety workers, vaccination of, 222t, 301  
Purified subunits, 14t-15t, 17  
*Purpura fulminans*, 335. See also *Neisseria meningitidis*.  
Q fever, bioterrorism potential, 83t  
RabAvert (PCECV), 420t-421t  
CPT and ICD-9-CM codes, 139t  
safety, 422  
Rabies, 417-423  
clinical features, 417-418  
epidemiology and transmission, 418, 426t-427t

Rabies (*continued*)

- incubation period, 417, 418
- nomenclature, 471t
- pathogen, 417
- vaccines for, 17, 419-423, 420t-421t. See also *Rabies immune globulin, human (HRIG)*.
  - background on immunization program, 418-419
  - contraindications/precautions, 172t, 422
  - CPT and ICD-9-CM codes, 139t
  - efficacy/immunogenicity, 422
  - postexposure prophylaxis, 419, 426t-427t
    - precautions, 172t
    - regimens, 428t-429t
  - pre-exposure prophylaxis, 419, 424t-425t
  - recommendations, 422-423, 424t-429t
  - safety, 422
- Rabies immune globulin, human (HRIG), 419-422
  - CPT and ICD-9-CM codes, 141t
  - efficacy/immunogenicity, 422
  - interval for receipt of live vaccines after, 165t
  - regimens, 428t-429t
- Ramsay Hunt syndrome, 374
- Reactions. See *Adverse events*.
- Reassortment, 16
- Recall and tracking systems, 116-118
- Recombinant vaccines, 14t-15t
- Recombivax HB (HepB), 298t-300t
  - cost of (purchase price), 150t
  - CPT and ICD-9-CM codes, 137t
  - efficacy/immunogenicity, 296-297
- Recommendations, 55-58, 155-177. See also *specific vaccines*.
  - agencies involved with, 55-58, 56
  - contraindications and precautions, 167-168, 169t-177t
  - current updates, 57
  - general recommendations, 57, 155-177
  - general rules for vaccination, 155-166
    - exceptions to, 155-163
  - Healthy People 2010* objectives, 88, 90t-93t
  - limitations of, ix
  - National Vaccine Plan, 58
  - publications on, 57-58
  - schedules for routine vaccinations, 179, 180t-192t
  - on vaccine handling, 112t-115t
  - vs package insert information, 53-54, 195-196
- Reconstituted vaccines, notation conventions, x
- Red Book (Report of the Committee on Infectious Diseases)*, viii-ix, 57, 462
- References and readings, 461-462. See also *Resources on vaccines; and reading lists at end of each chapter*.
  - Pink Book (Epidemiology and Prevention of Vaccine-Preventable Diseases)*, viii-ix, 57
  - Red Book (Report of the Committee on Infectious Diseases)*, viii-ix, 57
  - Vaccines* (Plotkin, Orenstein, and Offit, eds.), viii
- Refrigerators, general rules regarding, 111-116
- Refugees, international, 210-211

- Refusal of vaccination, 228-232
  - Refusal to Vaccinate* form, 231
- Registries. See *Immunization Information Systems (IISs)*.
- Reminder, recall, and tracking systems, 116-118
- Renal disease, end-stage, hepatitis B vaccination and, 301
- Report of the Committee on Infectious Diseases ("Red Book")*, viii-ix, 57, 462
- Reportable Events Table, 100t-101t
- Resources on vaccines, 459-463
  - advocacy, implementation, and safety, 460-461
  - books, 461-462
  - coverage and assessment, 461
  - governmental agencies, 459-460
  - international agencies, 460
  - manufacturers, 462-463
  - professional associations, 460
  - state health department immunization programs, 463
- RespiGam (RSV immune globulin, IV), 141t
- Respiratory papillomatosis, recurrent, HPV and, 307, 308
- Respiratory syncytial virus (RSV), monoclonal antibody to (RSVmA), 19, 147t
- Respiratory syncytial virus (RSV) immune globulins, 141t
  - interval for receipt of live vaccines after, 164t-165t
- REST (Rotavirus Efficacy and Safety Trial), 350-351
- Reye syndrome, 171t, 174t, 221t, 324, 325, 370
- Rhesus rotavirus vaccine, tetravalent. See *RRV-TV*.
- RhoGAM (IM), 165t
- Ricin toxin, bioterrorism potential, 83t
- Rickettsia prowazekii*, bioterrorism potential, 83t
- Risks and benefits of vaccines
  - communicating about, 223-228
  - in impaired immunity, 193
  - public health risk of vaccine refusals, 223, 230, 232-233, 238
  - safety and utility of vaccines, 223-224, 224
  - thought processes about, 225-227
- Rose spots, 442
- Rotarix (rotavirus, human; HRV), 350, 352t-353t
  - CPT and ICD-9-CM codes, 139t
- RotaShield (RRV-TV), 66-67, 349
- RotaTeq (PRV), 350, 352t-353t. See also *Rotavirus, vaccines for*.
  - cost of (purchase price), 151t
  - CPT and ICD-9-CM codes, 139t, 148t
  - efficacy/immunogenicity, 350-351
  - handling, 114t
  - minimum ages and intervals for, 160t
- Rotavirus, 347-355
  - clinical features, 348
  - epidemiology and transmission, 348-349
  - nomenclature, 471t
  - pathogen, 347-348
  - vaccines for, 352t-353t
    - background on immunization program, 349-350
    - contraindications/precautions, 172t, 354
    - cost-benefit analysis, 350
    - cost of (purchase price), 151t
    - CPT and ICD-9-CM codes, 139t, 148t

Rotavirus (*continued*)

- efficacy/immunogenicity, 350-351
  - handling and storage, 113t, 114t, 353t
  - human (HRV), 350, 352t-353t
    - serial passage of, 13
  - interval for receipt of antibody-containing products, 164t-165t
  - intussusception and, 66-67, 101t, 349
  - minimum ages and intervals for, 158t
  - pentavalent (PRV), 350, 352t-353t
  - recommendations for general use, 354-355
  - reportable events, 101t
  - safety, 351-354
    - schedule for, 180t, 185t
- Rotavirus Efficacy and Safety Trial (REST), 350-351
- Routes of inoculation, 17, 23
  - mistaken, valid dose count and, 163
- Routine vaccines, 267-403
  - schedules for. See *Schedules for routine immunizations*.
- RRV-TV (rhesus rotavirus vaccine, tetravalent), 66-67, 349
- RSV. See *Respiratory syncytial virus (RSV)*.
- Rubella, 326-335
  - clinical features, 328
  - criteria for immunity, 334t
  - epidemiology and transmission, 329
  - Healthy People 2010* objectives for, 92t
  - morbidity and mortality from, 46t
  - pathogen, 326
  - in pregnant women, 328
  - vaccines for, 332t-333t. See also *MMR vaccines*.
    - background on immunization program, 329-330
    - combination, 330, 388t-391t
    - CPT and ICD-9-CM codes, 139t
    - efficacy/immunogenicity, 330
    - recommendations for use, 333-335
    - reportable events, 100t
    - safety, 331-333
- Rubeola. See *Measles*.
- Rules for vaccination. See *Recommendations*.
- Sabin Vaccine Institute (SVI), 461
- Safety net. See *Vaccine safety net*.
- Safety of vaccines. See also *Vaccine safety net; and specific vaccines*.
  - advocacy, implementation, and safety organizations, 460-461
  - definitions of, 223-224
  - ISRC findings, 68t-69t
    - probability and utility concepts, 224-225, 224
- Salicylate use, as contraindication/precaution, 171t, 174t, 221t, 324, 370
- Salmonella enterica*. See *Salmonella typhi*.
- Salmonella typhi*, 17, 442-443, 471t. See also *Typhoid fever*.
  - bioterrorism potential and US vaccine status, 82t
- Schedules for routine immunizations, 179, 180t-192t. See also *specific vaccines*.
  - adults, by age group, 189t-190t
  - adults, by medical condition, 191t-192t
  - catch-up schedule, children age 4 months-6 years, 185t-186t

Schedules for routine immunizations (*continued*)

- catch-up schedule, children age 7-18 years, 187t-188t
  - children, age 0-6 years, 180t-182t, 362t-363t
  - children, age 7-18 years, 183t-184t
- School mandates, 107-108
- Screening for contraindications/precautions/other problems, 122, 124t-125t
- Section 317 Funds, 72, 119
- Seizure, as contraindication, 169t
- Serial passage, 13-16
- Seroconversion, 30, 289
  - testing for, 166
- Serotype replacement, 43
- Sharps use and precautions, 102-106
- Shigella*, bioterrorism potential, 83t
- Shingles. See *Zoster (herpes zoster; shingles)*.
- Shingles Prevention Study, 377
- Shortages of vaccines, 74-76, 78t-81t
  - current information on, 76
- Side effects. See *Adverse events*.
- SIDS. See *Sudden infant death syndrome*.
- Smallpox, 423-442
  - bioterrorism potential, 43-44, 82t, 430
  - clinical features, 423-430
  - diagnosis, 430, 432t-433t
  - epidemiology and transmission, 430-431
  - eradication of, 43, 430
  - extinction as goal for, 43-44
  - hemorrhagic, 423
  - immune globulin (vaccinia immune globulin, VIG), 141t, 439-440
  - last natural case, 43
  - malignant, 423
  - modified, 430
  - morbidity and mortality from, 46t
  - nomenclature, 471t
  - pathogen, 423
  - vaccines for, 431-437, 436t-437t
    - contraindications/precautions, 172t-173t, 206, 438-439
    - CPT and ICD-9-CM codes, 139t
    - efficacy/immunogenicity, 437
    - handling and administration, 123, 434-435
    - injury compensation program, 439-440
    - liability protection for, 439
    - recommendations, 440-442
    - safety, 437-440
    - schedule for, 436t-437t
    - Smallpox Response Teams, 440-441
    - US vaccine status, 82t
    - vs chickenpox, 432t-433t

Special circumstances, 193-222
  - health care personnel, 211-214
  - hematopoietic stem cell transplantation and leukemia, 203
  - HIV infection, 200-203, 202t
  - impaired immunity
    - general considerations, 193-196
    - specific states other than HIV infection, 196-200

- Special circumstances (*continued*)  
 international adoptees, refugees, and immigrants, 210-211  
 other special circumstances, 216, 221t-222t  
 pregnancy and breast-feeding, 203-207, 208t-209t  
 preterm and low birth weight infants, 207-210  
 travel, 214-216, 218t-220t
- Specialized vaccines, 405-457
- Standards, principles, and regulations, 87-100  
 adult immunization practices, standards, 95-96, 96t  
 Bloodborne Pathogens Standard, 102-107  
 federal requirements regarding vaccination, 104t-105t  
*Healthy People 2010*, 87-88, 90t-93t  
 National Childhood Vaccine Injury Act, 65, 96-102  
 Occupational Safety and Health Administration, 102-107  
 pediatric immunization practices, standards, 88-95  
 school mandates and state legislation, 107-108
- Standing orders, 118-119  
 for emergencies, 130, 132t-133t
- Staphylococcus aureus*  
 bioterrorism potential, 83t  
 secondary infections in varicella, 365
- State and local funds for vaccination, 71, 72  
 state financing models, 73-74, 73
- State health department immunization program web sites, 463
- State legislation on vaccinations, 107-108
- Steroids, impaired immunity and, 198
- Stockpile of vaccines, CDC, 76, 411, 431, 434
- Storage of vaccines, 111-116, 112t-115t, 117t. See also *specific vaccines*.
- Streptococcus pneumoniae*, 17, 355-364, 470t  
 clinical features, 355-356  
 epidemiology and transmission, 356  
*Healthy People 2010* objectives for, 92t  
 immunocompromised individuals and, 198  
 morbidity and mortality from, 46t, 356  
 pathogen, 355  
 replacement disease, 357  
 serotypes and, 46, 347  
 vaccines for, 357, 358t-359t. See also *Pneumococcal vaccines*.  
 background on immunization program, 357  
 efficacy/immunogenicity, 357-360  
 recommendations for general use, 360-364  
 safety, 360  
 schedule for, 360-361, 362t-363t
- Subcutaneous (SC) administration of vaccines, 123, 126  
 preferred sites and needle length, 128t-129t
- Subunits  
 engineered, 14t-15t, 18  
 purified, 14t-15t, 17
- Sudden infant death syndrome (SIDS), vaccinations and, 69t, 258
- Supplies for emergency situations, 132t-133t
- Supply of vaccines, 74-76, 78t-81t
- Surrogates of protection, 37-39
- SV40 contamination of polio vaccine, 68t, 256-257
- Swine flu vaccination, Guillain-Barré syndrome and, 251
- Synagis (RSV immune globulin, monoclonal, IM), 141t
- Syncope, 130, 311
- T-dependent response, 31
- T-independent antigens and responses, 25, 31
- Task Force on Safer Childhood Vaccines (TFSCV), 63t
- TB. See *Tuberculosis*.
- Tc cells. See *Cytotoxic T cells*.
- Td (tetanus, diphtheria) vaccine, 276t-277t  
 contraindications/precautions, 169t, 275, 278  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 139t  
 handling and storage, 112t, 277t  
 minimum ages and intervals for, 159t  
 recommendations for use, wound management, 282t-283t  
 safety, 275, 278  
 schedule for, 277t  
 adults, by age, 189t  
 adults, by medical condition/indication, 191t  
 catch-up, children age 7-18 years, 187t  
 shortages of, recent, 80t-81t
- Tdap vaccine, 272t-274t. See also *Adacel*; *Boostrix*; *DTaP*.  
 approval for adolescents, 271  
 contraindications/precautions, 167, 173t, 275, 278  
 cost of (purchase price), 151t  
 handling and storage, 114t, 274t  
 health care workers, vaccination of, 214  
 intervals for vaccination, 155-156  
 minimum ages and intervals for, 159t  
 recommendations for general use, 278-280, 282t-283t  
 safety, 275-278  
 schedule for, 187t-192t, 273t, 279-280
- Terminology. See *Nomenclature*.
- Terrorism, potential agents of, 76-77, 82t-83t
- Tetanus, 267-280  
 clinical features, 268  
 epidemiology and transmission, 269  
*Healthy People 2010* objectives for, 92t  
 morbidity and mortality from, 46t  
 pathogen, 267  
 toxin, 267  
 toxoid. See *Tetanus toxoid (TT)*.  
 vaccination for travel, 215  
 vaccines for, 272t-274t, 276t-277t. See also *DT*; *Tetanus toxoid (TT)*.  
 adult. See *Tdap vaccine*.  
 background on immunization program, 270  
 children/infants. See *DTaP vaccine*.  
 contraindications/precautions, 275-278  
 CPT and ICD-9-CM codes, 136t, 139t  
 efficacy/immunogenicity, 271-275  
 nomenclature, 470t  
 recommendations for general use, 278-280, 282t-283t  
 reportable events, 100t  
 safety, 275-278  
 toxoid-containing, number of doses, reactogenicity and, 162

- Tetanus immune globulin (TIG), 268, 282t-283t  
 CPT and ICD-9-CM codes, 141t  
 for HIV-infected children at risk for tetanus, 196  
 interval for receipt of live vaccines after, 165t  
 recommendations for use, wound management, 282t-283t
- Tetanus Toxoid Adsorbed, 276t-277t  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 139t
- Tetanus toxoid (TT), 276t-277t  
 contraindications/precautions, 169t, 275, 278  
 cost of (purchase price), 151t  
 CPT and ICD-9-CM codes, 136t, 139t  
 recommendations for use  
   for pregnant women, 207  
   for wound management, 282t-283t  
 safety, 275, 278  
 schedule for, 277t  
 storage, 277t
- Th cells (helper T lymphocytes), 26-28, 27
- Thimerosal. See also *specific vaccines*.  
 autism and, 245-249, 247, 248  
 organizations opposed to antithimerosal legislation, 250t  
 safety findings, 68t, 69
- Thrombocytopenia/thrombocytopenic purpura  
 MMR vaccine and, 331, 333  
 as precaution, 171t
- TIG. See *Tetanus immune globulin*.
- Timeliness  
 defined, 58  
 monitoring, 58-62
- TIV (trivalent inactivated influenza virus vaccine), 316t-320t, 321. See also  
*Influenza, vaccines for; TIV*.
- TLRs. See *Toll-like receptors (TLRs)*.
- Toll-like receptors (TLRs), 25, 31
- Topical anesthetics, 127
- Toxins  
 antibodies to, 39  
 diphtheria, tetanus, and pertussis, 267-268  
 endotoxin, *N meningitidis*, 335  
 neutralization of, 23
- Toxoid vaccines, 14t-15t
- Tracheal cytotoxin, 268
- Tracking systems, 116-118
- Transplantation, impaired immunity and  
 hematopoietic stem cell transplantation, 203, 204t-205t  
 solid organ transplantation, 198-199
- Travel, vaccination for, 214-216, 218t-220t, 292, 424t, 445, 451
- TriHIBit (DTaP/Hib), 388t-391t  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t
- Tripedia (DTaP), 272t-274t  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t  
 efficacy, 271
- Trivalent inactivated influenza virus vaccine. See *TIV*.
- TT. See *Tetanus toxoid (TT)*.
- Tuberculosis (TB), 454t  
 nomenclature, 471t  
 untreated, as precaution for vaccination, 171t, 174t, 333, 370, 378
- Tularemia, bioterrorism potential and US vaccine status, 82t
- TViPSV. See *Typhim Vi (typhoid Vi polysaccharide vaccine)*.
- Twinrix (HepA-HepB), 388t-391t  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t
- Ty21a (typhoid vaccine), 446t-447t  
 contraindications/precautions, 174t, 196  
 efficacy/immunogenicity, 444  
 interval for receipt of antibody-containing products, 164t-165t  
 safety, 444-445
- Typhim Vi (typhoid Vi polysaccharide vaccine; TViPSV), 446t-447t  
 contraindications/precautions, 174t  
 CPT and ICD-9-CM codes, 139t  
 efficacy/immunogenicity, 444  
 safety, 444
- Typhoid fever, 442-447  
 clinical features, 442-443  
 epidemiology and transmission, 443  
 nomenclature, 471t  
 pathogen, 442  
 vaccines for, 444-445, 446t-447t  
   background on immunization program, 443  
   contraindications/precautions, 174t, 445  
   CPT and ICD-9-CM codes, 139t  
   efficacy/immunogenicity, 444  
   engineered attenuation of, 16  
   interval for receipt of antibody-containing products, 164t-165t  
   recommendations, 445  
   safety, 444-445
- Typhus fever, bioterrorism potential, 83t
- Universal precautions, 106
- US Agency for International Development (USAID), 460
- US Food and Drug Administration. See *Food and Drug Administration (FDA)*.
- Utility of vaccines, 224-225, 224
- Vaccinate Your Baby, 461
- Vaccination. See also *Immunization; Vaccinology*.  
 basic concepts, 13-48  
 costs-benefit analysis of, 47, 48t  
 goals of, 43-45, 44t  
 postexposure, for bioterrorism agents, 77  
 public health impact of, viii, 45-47, 46t, 48t, 237
- Vaccine Adverse Event Reporting System (VAERS), 63-64, 94, 98-99, 459
- Vaccine and Treatment Evaluation Unit (VTEU), 56
- Vaccine development and licensure, 49-54. See also *Vaccine infrastructure in the United States*.  
 agencies involved with, 55-58, 56  
 Biologics License Application (BLA), 53

- Vaccine development and licensure (*continued*)  
 clinical trials, 51-53, 52  
 package insert (PI), 53-54  
 process of, schematic, 50
- Vaccine immunology. See *Immune response*.
- Vaccine Information Statements (VISs), 99-102, 104t
- Vaccine infrastructure in the United States, 49-86  
 bioterrorism, 76-77, 82t-83t  
 financing, 67-74, 70t, 71  
 monitoring vaccine delivery, 58-62  
 monitoring vaccine effectiveness, 62  
 policy and recommendations, 55-58, 56  
 supply, 74-76, 78t-81t  
 vaccine development and licensure, 49-54  
 vaccine safety net, 62-67, 63t
- Vaccine Injury Compensation Program (VICP), 56, 94, 97-98, 459  
 administration and review of, 66, 76  
 covered vaccines, 98
- Vaccine Injury Table (VIT), 97, 251
- Vaccine policy, agencies involved with, 55-58, 56. See also *Recommendations*.
- Vaccine practice, 111-153  
 coding, billing, and vaccine costs, 131-135, 134t, 136-142t, 144-148t, 153t  
 emergencies, dealing with, 130-131, 132t-133t  
 screening, 122, 124t-125t  
 vaccine administration, 122-129, 126, 128t-129t  
 vaccine delivery, improving, 116-118  
 vaccine handling, 111-116, 112t-115t
- Vaccine-preventable diseases  
*Healthy People 2010* objectives, 87-88, 92t-93t  
 monitoring activity of, 62  
 morbidity and mortality from, 46t, 95  
 reduction with childhood vaccination programs, 48t  
 vaccination of patients with previous disease history, 162
- Vaccine protest organizations, 233-235, 234, 235t, 236t
- Vaccine recommendations. See *Recommendations*.
- Vaccine registries. See *Immunization Information Systems (IISs)*.
- Vaccine Safety DataLink (VSD), 64-65
- Vaccine safety net, 62-67, 63t  
 in action, 66-67  
 ISRC safety findings, 68t-69t
- Vaccine(s). See also *Immunization; Vaccination; and specific vaccines*.  
 administration. See *Administration of vaccines*.  
 anxiety, pain and fever, dealing with, 127  
 classification, 13, 14t-15t  
 combination. See *Combination vaccines*.  
 communicating about, viii, 223-228, 224, 229t  
 component, 14t-15t, 17-18  
 concerns about, addressing, 223-266  
 costs/cost-benefit analyses. See *Costs*.  
 delivery. See *Delivery of vaccines*.  
 development. See *Vaccine development and licensure*.  
 engineered agents, 14t-15t  
 equivalence of different manufacturers, 157  
 funding for. See *Financing*.
- Vaccine(s) (*continued*)  
 handling of, 111-116, 112t-115t  
 inactivated, 14t-15t, 17-18, 20t-22t  
 introduction to, 13-48  
 licensure. See *Vaccine development and licensure*.  
 live, 13-17  
 vs inactivated, 14t-15t, 20t-22t, 36  
 necessity for, 235-237  
 nomenclature, 470t-471t  
 polysaccharide, 17-18  
 recombinant, 14t-15t  
 recommendations regarding. See *Recommendations*.  
 resources on, 459-463. See also *Resources on vaccines*.  
 schedules for. See *Schedules for routine immunizations*.  
 shortages of, 74-76, 78t-81t  
 sources of information on, 459-463  
 specificity of, 29-30  
 supply/shortages, 74-76, 78t-81t  
 whole-agent, 14t-15t, 17
- Vaccines and Related Biological Products Advisory Committee (VRBPAC), 53, 56, 459
- Vaccines for Children (VFC) Program, 55, 70-72, 89, 459
- Vaccines (Plotkin, Orenstein, and Offit, eds.), viii, 462
- Vaccinia immune globulin (VIG), 141t, 439-440
- Vaccinia virus, 41. See also *Smallpox*.
- Vaccinology, 13-48. See also *Immune response; Immunization*.  
 additional concepts, 37-45  
 correlates of protection, 37-39  
 goals of immunization programs, 43-45, 44t  
 herd immunity, 39-43, 41-42  
 basic vaccine immunology, 19-37  
 immunization, 13-19  
 public health impact of vaccination, 45-47, 46t, 48t, 237
- VAERS. See *Vaccine Adverse Event Reporting System*.
- Vaqa (HepA), 290t-291t  
 cost of (purchase price), 149t  
 CPT and ICD-9-CM codes, 136t  
 efficacy/immunogenicity, 289
- Vaqa (HepB), CPT and ICD-9-CM codes, 136t
- Varicella, 364-373  
 chickenpox and, 364-366  
 clinical features, 364-366  
 criteria for immunity, 371t  
 diagnosis, 432t-433t  
 epidemiology and transmission, 366  
 health care workers, vaccination for, 213  
*Healthy People 2010* objectives for, 92t  
 herpes zoster (shingles) and, 364, 365-366, 373. See also *Zoster (herpes zoster; shingles)*.  
 latent infection, 364  
 reactivation of, 365-366  
 morbidity and mortality from, 46t  
 nomenclature, 471t  
 passive immunoprophylaxis for, 372-373

- Varicella (*continued*)
- pathogen, 364
  - prior history of, vaccination of patients with, 162
  - in vaccinated individuals (breakthrough or vaccine-modified varicella), 365
  - vaccine for, 368t
    - action mechanisms, 35-36
    - background on immunization program, 366-367
    - combination, 388t-391t
    - contraindications/precautions, 370
    - cost-benefit of vaccination, 367
    - cost of (purchase price), 152t
    - CPT and ICD-9-CM codes, 139t
    - efficacy/immunogenicity, 367-369
    - first and second doses, 30
    - handling and storage, 114t, 367t
    - impaired immunity patients and, 193, 197
    - interval for receipt of antibody-containing products, 164t-165t
    - minimum ages and intervals for, 159t
    - mixups with zoster vaccine, 166
    - one-dose varicella program, 46
    - persistence of antibodies, 30
    - postexposure vaccination, 369, 372
    - recommendations for general use, 370-373
    - reportable events, 101t
    - safety, 369-370
    - schedule for
      - adults, by age, 189t
      - adults, by medical condition/indication, 191t
      - catch-up, children age 4 months-6 years, 186t
      - catch-up, children age 7-18 years, 183t, 187t
      - children, age 0-6 years, 180t
      - children, age 7-18 years, 183t
    - serial passage of, 13
    - shortages of, recent, 81t
    - vs zoster (shingles) vaccine, 36
    - vs smallpox, 432t-433t
  - Varicella-zoster immune globulin (VariZIG), 372-373
    - adverse reactions, local, 372-373
    - interval for receipt of live vaccines after, 165t
    - phone number for obtaining under investigational new drug protocol, 372
    - post-exposure, for immunosuppressed individuals, 196, 372
    - recommendations for use, 207, 372
    - safety, 373
  - Varicella-zoster virus (VZV), 364, 373, 471t. See also *Varicella*.
  - Variola major, 423-430
  - Variola minor (alastrim), 430
  - Variola sine eruptions, 430
  - Variola virus, 82t, 471t. See also *Smallpox*.
  - Varivax (varicella vaccine), 368t. See also *Varicella, vaccine for*.
    - cost of (purchase price), 152t
    - CPT and ICD-9-CM codes, 139t
  - VariZIG. See *Varicella-zoster immune globulin (VariZIG)*.
  - Venoglobulin-S (immune globulin, human, IV), 141t
  - Veterinarians, vaccination of, 221t, 424t
  - VFC. See *Vaccines for Children (VFC) Program*.
  - Vibrio cholera*, 454t
  - VICP. See *Vaccine Injury Compensation Program*.
  - Viral encephalitis, bioterrorism potential, 83t
  - Viral hemorrhagic fevers, bioterrorism potential, 82t
  - Viscerotropic disease, vaccine-associated, 451
  - VISs. See *Vaccine Information Statements*.
  - Vivaglobin (immune globulin, human), 141t
  - Vivotif (typhoid vaccine; Ty21a), 446t-447t
    - CPT and ICD-9-CM codes, 139t
    - efficacy/immunogenicity, 444
    - safety, 444-445
  - Voices for Vaccines, 461
  - Vomito negro, 448
  - VRBPAC (Vaccines and Related Biological Products Advisory Committee), 53, 56, 459
  - VSD. See *Vaccine Safety DataLink*.
  - VTEU. See *Vaccine and Treatment Evaluation Unit*.
  - Waiting period after vaccination, 130
  - Waning immunity, 239, 271, 365
  - Water safety threats, bioterrorism potential, 83t
  - Week(s), definition of, x
  - Whole-agent vaccines, 14t-15t, 17
  - Whooping cough. See *Pertussis*.
  - Woolsorter's disease, 405
  - World Health Organization (WHO), 49, 460
    - vaccine recommendations for travel, 216
  - X-linked agammaglobulinemia, 197
  - Yeast, baker's, allergy to, 170t, 312
  - Yellow fever, 448-452
    - certificates of vaccination, 451-452
    - clinical features, 448
    - epidemiology and transmission, 448-449
    - nomenclature, 471t
    - pathogen, 448
    - vaccines for, 449-452, 450t
      - adverse events, 65, 450-451
      - background on immunization program, 449
      - contraindications/precautions, 174t, 196, 451
      - CPT and ICD-9-CM codes, 139t
      - efficacy/immunogenicity, 449
      - interval for receipt of antibody-containing products, 164t-165t
      - intervals for vaccination, 155
      - polyclonal immune globulin and, 19
      - precautions, 196
      - recommendations, 216, 451-452
      - safety, 449-451
  - Yellow fever virus (YFV), 448
  - Yersenia pestis*, 82t, 454t
  - YF-Vax (yellow fever vaccine), 449-452, 450t
    - CPT and ICD-9-CM codes, 139t

Zostavax (zoster vaccine), 375-378, 376t  
cost of (purchase price), 152t  
CPT and ICD-9-CM codes, 139t

Zoster (herpes zoster; shingles), 373-378. See also *Varicella*.  
clinical features, 373-374  
epidemiology and transmission, 374-375  
pathogen, 373  
postherpetic neuralgia (PHN) and, 365, 373, 374  
vaccine for, 376t  
background on immunization program, 375  
contraindications/precautions, 174t, 196, 377-378  
cost-benefit of vaccination, 375  
cost of (purchase price), 152t  
CPT and ICD-9-CM codes, 139t  
efficacy/immunogenicity, 377  
handling and storage, 114t, 376t  
interval for receipt of antibody-containing products, 164t-165t  
minimum ages and intervals for, 160t  
mixups with varicella vaccine, 166  
nomenclature, 471t  
recommendations for general use, 378  
safety, 377-378  
schedule for, 189t, 191t, 376  
vs varicella vaccine, 36